Project Grant R01HL172489
Award Date
9/9/24
Completion Date
5/31/28
Dollars Obligated
$2.7M
Federal Agency
National Heart Lung and Blood Institute
Federal Grant Program
93.837
Assistance Type
Project Grant
Place of Performance
Boston, MA 02115, USA
Similar Awards
This federal Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), part of the Cardiovascular Diseases Research program (CFDA 93.837), provides $300,000 to Gigamune, Inc. to develop an in vivo gene therapy for sickle cell disease. The project aims to test a novel lentiviral vector technology for efficiently editing hematopoietic stem cells to knockout the BCL11A enhancer, a key genetic target for sickle cell treatment. Through in vitro assays, the Phase I effort will...
This Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), part of the Cardiovascular Diseases Research federal grant program (CFDA 93.837), aims to evaluate methods for improving the homing and engraftment efficiency of CD34+ cells from sickle cell disease (SCD) patients. The $128,100 award to the New York Blood Center, Inc. will support research to determine if co-infusing the CD34+ cells with their flow-through accessory cells, normally discarded after CD34+ cell...
The National Heart, Lung, and Blood Institute (NHLBI) awarded a $814,209 project grant under the Cardiovascular Diseases Research (CFDA 93.837) program to the Fred Hutchinson Cancer Center in Seattle, Washington. The goal of this 4-year project, starting May 1, 2025, is to develop and evaluate targeted nanoparticles for in vivo hematopoietic stem cell gene therapy to treat genetic blood diseases and disorders. Key objectives include optimizing nanoparticle formulations loaded with gene editing...
This federal Project Grant award from the National Heart, Lung, and Blood Institute (CFDA 93.837 Cardiovascular Diseases Research) provides $169,156 to The Washington University in St. Louis to support a 5-year research program focused on optimizing hematopoietic stem cell transplantation (HSCT) to treat non-malignant diseases, particularly sickle cell disease (SCD). The key objectives are to: 1) Evaluate novel stem cell mobilization regimens combining VLA-4 and CXCR4 inhibition to generate...
This Project Grant award from the National Heart, Lung, and Blood Institute (CFDA 93.837 Cardiovascular Diseases Research program) provides $483,852 to The General Hospital Corporation, doing business as Massachusetts General Hospital (MGH), to develop a high-throughput platform technology for measuring the kinetics and equilibrium concentration of sickle hemoglobin polymerization in single red blood cells. The platform will enable optimization of emerging sickle cell disease treatments, such as...
This Project Grant award of $734,607 from the National Heart, Lung, and Blood Institute (CFDA 93.837 Cardiovascular Diseases Research) aims to elucidate the key endothelial mechanisms that direct hematopoietic stem cells (HSCs) across the blood vessel wall and into their niche. The research, conducted by Boston Medical Center Corporation, will use high-resolution live cell imaging, structure-function studies, and in vivo proximity-dependent biotinylation in zebrafish to define the endothelial...
This Project Grant award of $765,622 from the National Heart, Lung, and Blood Institute (CFDA 93.837 - Cardiovascular Diseases Research) supports the development of orally bioavailable protein degraders to elevate fetal hemoglobin (HBF) levels and treat sickle cell disease (SCD). The primary awardee, Yale University, will collaborate with The Children's Hospital of Philadelphia to test the degraders in primary human erythroid cells and mouse models. This research aims to discover new small...
This Project Grant award from the National Heart, Lung, and Blood Institute (CFDA 93.837 Cardiovascular Diseases Research) provides $2,250,837 to Seattle Children's Hospital to develop lipid nanoparticles (LNPs) that can deliver CRISPR/Cas9 gene editing tools to liver sinusoidal endothelial cells (LSECs) to correct mutant Factor VIII (F8) genes and treat hemophilia A. The project aims to permanently correct F8 gene mutations using LNPs and gene editing, first in hemophilia A mouse models and...
This Project Grant award from the National Heart, Lung, and Blood Institute (CFDA 93.837 Cardiovascular Diseases Research) provides $296,892 to support research aimed at understanding the molecular regulation of lymphoid lineage priming in both steady state and regenerative hematopoiesis. The research, conducted by The Children's Hospital Corporation (Boston Children's Hospital), will use single-cell sequencing and lineage tracing approaches to elucidate how the transcription factor TCF15...
The federal Project Grant award in the amount of $617,367 was provided by the Defense Health Agency under the Military Medical Research and Development (CFDA 12.420) program. The award is being used by the Children's Hospital Corporation, doing business as Boston Children's Hospital, to conduct research on "BASE EDITING TO IMPROVE CONDITIONING AND TRANSPLANT OF BONE MARROW FAILURE PATIENTS". The research project aims to leverage innovative gene editing techniques to enhance the...